KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF
Status unconfirmed · Phase 1/Phase 2
Conditions studied: Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis
In brief
This study evaluates KRT-232 in Combination With TL-895 for the Treatment of Relapsed or Refractory Myelofibrosis and KRT-232 for the Treatment of JAK Inhibitor Intolerant Myelofibrosis.
Key facts
- Study ID
- NCT04640532
- Run by
- Kartos Therapeutics, Inc.
- People needed
- 116
- Starts
- 2020-11-17
- Expected to finish
- 2025-07-24
- Last updated by the study team
- 2022-05-09
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Confirmed diagnosis of primary MF, post-PV MF, or post-ET MF, (WHO 2016)
- ECOG ≤ 2
- Cohort 1 and Cohort 2: R/R following JAK inhibitor treatment
- Cohort 3: patients who are intolerant to JAK inhibitor treatment
You may not qualify if…
- Prior treatment with MDM2 inhibitors or p53-directed therapies
- Prior treatment with a BCR-ABL, phosphoinositide 3-kinase (PI3k), mammalian target of rapamycin (mTOR), bromodomain and extraterminal domain (BET), histone deacetylase (HDAC), or spleen tyrosine kinase (Syk) inhibitor
- Prior splenectomy
- Splenic irradiation within 3 months prior to the first dose of study treatment
- Clinically significant thrombosis within 3 months of screening
- Grade 2 or higher QTc prolongation
Where it is running
- University of Alabama at Birmingham School of Medicine, Division of Hematology and Oncology — Birmingham, Alabama, United States (enrolling)
- The Oncology Institute of Hope — Whittier, California, United States (enrolling)
- Lake City Cancer Center — Lake City, Florida, United States (enrolling)
- Carle Cancer Center — Urbana, Illinois, United States (enrolling)
- Columbia University Medical Center — Fort Lee, New Jersey, United States (enrolling)
- Memorial Sloan Kettering Cancer Center (MSKCC) — New York, New York, United States (enrolling)
- LKH Hochsteiermark — Leoben, Austria (enrolling)
- Meduni Wien, Univ. Klinik für Innere Medizin I — Vienna, Austria (enrolling)
- University Multiprofile Hospital for Active Treatment Dr. Georgi Stranski, Pleven — Pleven, Bulgaria (enrolling)
- University Multiprofile Hospital for Active Treatment Dr. Georgi Plovdiv — Plovdiv, Bulgaria (enrolling)
- Hematology Clinic Specialized Hospital for Active Treatment of Hematological Diseases, Sofia — Sofia, Bulgaria (enrolling)
- Chu Amiens Picardie Site Sud — Amiens, France (enrolling)
- CHU de Limoges Service Hématologie Clinique et Thérapie Cellulaire — Limoges, France (enrolling)
- CHU Nantes - Hôtel Dieu — Nantes, France (enrolling)
- CHU de Nice Hospital — Nice, France (enrolling)
- Hôpital Saint Louis — Paris, France (enrolling)
- Centre Hospitalier Lyon Sud — Pierre-Bénite, France (enrolling)
- University Hospital Halle (Saale), Department of Internal Medicine IV - Hematology and Oncology — Halle, Germany (enrolling)
- University Hospital Marburg, Department of Hematology, Oncology and Immunology — Marburg, Germany (enrolling)
- Moritz Kaposi General Hospital, Department of Hematology — Kaposvár, Hungary (enrolling)
- Szabolcs-Szatmar-Bereg County Hospitals and University Teaching Hospital, Department of Hematology — Nyíregyháza, Hungary (enrolling)
- Medical Center of the University of Pecs, 1st Department of Internal Medicine, Division of Hematology — Pécs, Hungary (enrolling)
- Fejer County St. Gyorgy University Teaching Hospital, Department of Internal Medicine III, Hematology — Székesfehérvár, Hungary (enrolling)
- Polyclinic S. Orsola-Malpighi — Bologna, Italy (enrolling)
- ASST Spedali Civili di Brescia — Brescia, Italy (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.